Update on Endothelin Receptor Antagonists in Hypertension

Area of Science:

• Pharmacology
• Nephrology
• Cardiology

Background:

• Endothelin receptor antagonists (ERAs) represent a therapeutic class targeting the endothelin pathway.
• The endothelin system plays a role in blood pressure regulation and renal function.

Purpose of the Study:

• To review recent data on endothelin receptor antagonists (ERAs) for hypertension and diabetic nephropathy.
• To assess the efficacy and tolerability of ERAs in these conditions.

Main Methods:

• Review of recent experimental and clinical data.
• Analysis of meta-analyses and clinical trial outcomes.

Main Results:

• ERAs significantly decrease blood pressure in essential and resistant hypertension.
• ERAs reduce albuminuria by 30-40% in diabetic nephropathy when added to renin-angiotensin system blockers.
• Tolerability issues, including fluid retention, edema, and liver toxicity, have limited ERA use.

Conclusions:

• Endothelin receptor blockade holds potential for hypertension and diabetic nephropathy management.
• Limited ongoing clinical programs and tolerability concerns necessitate further data to define ERAs' role.